Why the study?
Controlled trials for secondary prevention of sudden death comparing antiarrhythmics versus implantable cardioverter-defibrillators provide important clinical information on outcomes during follow-up but require subanalyses for detailed insights.
Cohort (n=389)
No
Answers are grounded in this paper and cite their sources.
Worst-phenogroup ICD patients face doubled mortality and shock risk; extends phenotyping for refined secondary-prevention stratification.
PURPOSE OF REVIEW: Controlled trials for secondary prevention of sudden death--Antiarrhythmics Versus Implantable Defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH)--have been published and subanalyses of them provide useful clinical information on the outcome during the follow-up of this population. RECENT FINDINGS: Results from a meta-analysis showed a significant risk reduction (RR) of 25 to 27% of total mortality (P < 0.001) and 50 to 52% of arrhythmic death (P < 0.001). Compared with amiodarone, patients treated with an implantable cardioverter-defibrillator (ICD) in AVID had a maximal benefit in survival when the ejection fraction (EF) was between 20 and 34%. In CIDS, the group of higher risk (older than 70 years, EF less than 3.5%, and New York Heart Association class III-IV) presented a 50% RR of mortality. It has been demonstrated that the imbalance in beta-blocker use cannot explain the better survival in the ICD patients. After 3 years the recurrence of arrhythmia was 64% in the ICD group of the AVID trial. Patients enrolled after an episode of ventricular tachycardia were more likely to have appropriate therapy during follow-up. Older age, lower blood pressure, history of atrial fibrillation, diabetes, congestive heart failure, and prior pacemaker were parameters used for high-risk stratification. Conversely, inducibility of ventricular tachyarrhythmias on electrophysiology did not predict death. SUMMARY: Patients with ICD after ventricular tachyarrhythmias have a 28% RR in total mortality. Individuals with EF between 20 to 34% received the highest benefit with ICD therapy.
No takes yet. Share an insight, caveat, or question.
Oscar et al. (2003) conducted a cohort in Heart failure with reduced or mildly reduced ejection fraction (n=389). Phenogroup 3 (severe heart failure progression) vs. Phenogroup 1 (oldest, ischemic cardiomyopathy, least symptomatic) was evaluated on All-cause mortality (HR 2.25, 95% CI 1.45-3.49, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: